Inflamalps Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 4

Inflamalps General Information

Description

Operator of a biopharmaceutical company intended to progress in the treatment of chronic inflammatory diseases. The company engages in discovering and developing novel molecules with a focus on ophthalmological and dermatological diseases, helping find reliable cures for such chronic diseases by leveraging technological development and professional research.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Route De L'Ile-Au-Bois 1A
  • 1870 Monthey
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • Route De L'Ile-Au-Bois 1A
  • 1870 Monthey
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inflamalps Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Inflamalps‘s full profile, request access.

Request a free trial

Inflamalps Patents

Inflamalps Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026209841-A1 Compounds such as n-hydroxyapiosporamide or didymellamides for use in the treatment of fungal infection such as candida Pending 01-Apr-2025
EP-4493204-A1 Aqueous extract from the aerial parts of a plant of the genus aster and uses thereof Pending 16-Mar-2022
WO-2023174981-A1 Aqueous extract from the aerial parts of a plant of the genus aster and uses thereof Inactive 16-Mar-2022
FR-3133536-A1 Aqueous extract of the aerial parts of a plant of the aster genus and its uses Active 16-Mar-2022
FR-3133536-B1 Aqueous extract of the aerial parts of a plant of the genus aster and its uses Active 16-Mar-2022 A61K36/28
To view Inflamalps’s complete patent history, request access »

Inflamalps Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inflamalps Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Inflamalps‘s full profile, request access.

Request a free trial

Inflamalps FAQs

  • When was Inflamalps founded?

    Inflamalps was founded in 2012.

  • Where is Inflamalps headquartered?

    Inflamalps is headquartered in Monthey, Switzerland.

  • What is the size of Inflamalps?

    Inflamalps has 10 total employees.

  • What industry is Inflamalps in?

    Inflamalps’s primary industry is Drug Discovery.

  • Is Inflamalps a private or public company?

    Inflamalps is a Private company.

  • What is Inflamalps’s current revenue?

    The current revenue for Inflamalps is .

  • How much funding has Inflamalps raised over time?

    Inflamalps has raised $1.89M.

  • Who are Inflamalps’s investors?

    Fondation The Ark and Waarde Capital have invested in Inflamalps.

  • When was Inflamalps acquired?

    Inflamalps was acquired on 01-Sep-2022.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process